MAP2K7 and neoplasm: Another consideration is that in certain genomic contexts, including some tumors with RAS mutations (ie, preclinical data of BRAF/RAS-WT tumor cells) [33], the MEK-ERK pathway may not be fundamental for tumor cell proliferation; thus, inhibition of the MEK-ERK pathway may not reduce the survival of certain tumor cells.